"Bharat Biotech has two proposals or ideas for development of a vaccine. One with an inactivated Zika virus and the other is a recombinant... It's a proposal. They have done some early work. In the next few months, we will closely monitor and work with them and see the progress. At the moment, we do not have a vaccine candidate," ICMR Director- General Soumya Swaminathan told reporters here.
When pointed out that it may take several years for the vaccine to come out, she said the process of developing a substance has to go through the regulatory steps, though the process can be expedited with various stakeholders joining the endeavour and in the Public Private Partnership (PPP) mode.
"I think now, because of the recognition that this is important and also the PPPs and various bodies agreeing to come together and work, I think if there is a promising vaccine lead, then we can get many different partners involved and take it forward more rapidly. Of course, it still has to go through the regulatory steps," she said.
"People are now talking about having platforms, create a vaccine platform. That's one of the advantages Bharat Biotech had. He (the company) had already been working on a Chikungunya vaccine.
"Because, Zika virus is quite similar, if he is able to adopt that platform, I think doing more basic research on vaccine platforms is probably equally important. Of course, it takes time... But, I think the timelines are shrinking," she said.
The most common symptoms of Zika virus disease, caused by mosquito bites, are fever, rash, joint pain and red eyes. There's no vaccine or specific treatment for the infection, known as Zika fever.
Swaminathan said surveillance and testing of people is being done to deal with Zika at present, besides looking at the issue of developing a vaccine.
"For Zika, at the moment, what we are doing is surveillance. Making sure that we equip our labs to be able to test for Zika. We want to find out if there is any Zika circulating. So, we are testing people who present with fever, just like a dengue but a dengue negative. We have not found any case so far, but we will continue this exercise," she said.
The ICMR hopes to get a live virus so that government labs can start working on it, she said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
